Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ferumoxytol-cleavable valine-citrulline-monomethyl auristatin E
- Development stage
- Preclinical
- Lead developer
- Stanford University
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Ferumoxytol-cleavable valine-citrulline-monomethyl auristatin E (also referred to as FCM or TNP) is an investigational theranostic nanoparticle conjugate developed by researchers at Stanford University for the treatment and magnetic resonance imaging (MRI) of glioblastoma. The agent consists of a superparamagnetic iron oxide nanoparticle core (ferumoxytol) conjugated via a cathepsin B-cleavable valine-citrulline dipeptide linker to the potent antimitotic toxin monomethyl auristatin E (MMAE). The ferumoxytol core acts as an MRI contrast agent, allowing non-invasive in vivo tracking of nanoparticle accumulation in the tumor. Upon internalization into glioblastoma cells, the linker is selectively cleaved by lysosomal cathepsin B, which is highly expressed in glioblastoma, releasing active MMAE to inhibit tubulin polymerization and induce tumor cell death while minimizing off-target systemic toxicity.
- Other names
- ferumoxytol-cleavable MMAEferumoxytol-valine-citrulline-monomethyl auristatin Etheranostic nanoparticlesTNP
Beyond the preview
Go deeper on ferumoxytol-cleavable valine-citrulline-monomethyl auristatin E.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ferumoxytol-cleavable valine-citrulline-monomethyl auristatin E.